<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: Drugs interfering with the renin-angiotensin system (<z:mp ids='MP_0011356'>RAS</z:mp>) have been shown to reduce the incidence of <z:hpo ids='HP_0001297'>stroke</z:hpo> in patients at risk and to afford neuroprotection in experimental <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>This study aimed to compare potential neuroprotective effects of systemic pretreatment with the angiotensin receptor blocker, <z:chebi fb="0" ids="3347">candesartan</z:chebi>, and the angiotensin-converting enzyme (ACE)-inhibitor, <z:chebi fb="0" ids="8774">ramipril</z:chebi>, in normotensive Wistar rats after focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, with special emphasis on the regulation of neurotrophins </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Equipotent subcutaneous doses of <z:chebi fb="0" ids="3347">candesartan</z:chebi> and <z:chebi fb="0" ids="8774">ramipril</z:chebi> were determined via inhibition of pressor responses to intravenously injected <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> (<z:chebi fb="0" ids="48432">Ang II</z:chebi>) or angiotensin I (Ang I), respectively </plain></SENT>
<SENT sid="3" pm="."><plain>Accordingly, animals were treated with <z:chebi fb="0" ids="3347">candesartan</z:chebi> (0.1 mg/kg body weight, twice daily), <z:chebi fb="0" ids="8774">ramipril</z:chebi> (0.01 and 0.1 mg/kg body weight, twice daily) or vehicle (0.9% saline, twice daily), respectively, 5 days prior to middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) with reperfusion </plain></SENT>
<SENT sid="4" pm="."><plain>Severity of <z:hpo ids='HP_0001297'>stroke</z:hpo> was estimated via <z:mpath ids='MPATH_124'>infarct</z:mpath> size [magnetic resonance imaging (MRI) 48 h after MCAO] and neurological outcome (24 h, 48 h after MCAO) </plain></SENT>
<SENT sid="5" pm="."><plain>Measurements of neurotrophins/receptors in brain tissue were performed 48 h after MCAO </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Pretreatment with <z:chebi fb="0" ids="3347">candesartan</z:chebi> and <z:chebi fb="0" ids="8774">ramipril</z:chebi> (low dose) did not reduce blood pressure during MCAO, whereas <z:chebi fb="0" ids="8774">ramipril</z:chebi> high dose did </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="3347">Candesartan</z:chebi>, but not <z:chebi fb="0" ids="8774">ramipril</z:chebi> at any dose, significantly reduced <z:hpo ids='HP_0001297'>stroke</z:hpo> volume and improved neurological outcome </plain></SENT>
<SENT sid="8" pm="."><plain>Poststroke <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein of the neurotrophin receptor, TrkB, were significantly elevated in animals treated with <z:chebi fb="0" ids="3347">candesartan</z:chebi>, but not <z:chebi fb="0" ids="8774">ramipril</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Systemic pretreatment with a sub-hypotensive, <z:mp ids='MP_0011356'>RAS</z:mp>-blocking dose of <z:chebi fb="0" ids="3347">candesartan</z:chebi> affords neuroprotection after focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, associated with increased activity of the neurotrophin BDNF/TrkB system </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="8774">Ramipril</z:chebi> at sub-hypotensive and hypotensive, <z:mp ids='MP_0011356'>RAS</z:mp>-blocking doses showed no significant neuroprotective effects </plain></SENT>
</text></document>